Updated:
Inhibikase Therapeutics
We are a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial...
Inhibikase Therapeutics
We are a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit”, has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. We have completed a non-human primate safety study and a bioequivalence clinical study in healthy volunteers to determine the doses of IKT-001 that are equivalent to imatinib. Our Phase 3 clinical study, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), has been initiated with the activation of a small number of sites and the recent commencement of patient pre-screening activities at those sites. Inhibikase is headquartered in Wilmington, DE with additional offices in Boston, Massachusetts.
General information
Firm type
Asset Manager
Year founded
2008
Location
Region
North America
Country
United States
City
Atlanta
Corporate office
Atlanta, GA, United States
Principals
Milton H. Werner
President & Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Inhibikase?
Inhibikase is not an investment firm; it is an operating biotech company. Capital allocation decisions — primarily R&D expenditure, clinical trial prioritization, and financing strategy — are made by CEO Milton Werner with board oversight. The board includes independent directors with pharmaceutical and public-company experience.
What is Inhibikase's lead drug candidate?
Risvodetinib (formerly IkT-148009) is Inhibikase's lead candidate. It is a c-Abl tyrosine kinase inhibitor delivered orally that crosses the blood-brain barrier. The drug is currently in Phase 2 trials for untreated Parkinson's disease, with topline data expected in the second half of 2024 per the company's public guidance.
How is Inhibikase funded?
Inhibikase raises capital through equity offerings on the Nasdaq and via grant funding from organizations such as the National Institutes of Health. The company has not generated product revenue. Its most recent public offering, closed in May 2024, raised approximately $4 million to extend the clinical runway for risvodetinib.
What is the relationship between Inhibikase and other kinase-inhibitor biotechs?
Inhibikase is completely independent. Its c-Abl kinase inhibitor approach for neurodegeneration is distinct from oncology-focused kinase inhibitors developed by companies like Novartis or Bristol Myers Squibb. The company's intellectual property around its prodrug platform and specific CNS-penetrant molecules is wholly owned, with no large-pharma partners as of mid-2024.
Is Inhibikase a family office or asset manager?
No. Despite being initially flagged in this context, Inhibikase is a publicly traded clinical-stage biopharmaceutical company. It operates as a drug developer, not a family office, pension fund, or asset manager. It manages its own clinical pipeline, not third-party capital, and does not allocate to external managers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: